Amylyx Pharmaceuticals, Inc. AMLX 深 沪
等待开盘 07-22 09:30:00 美东时间
8.21
-0.130
-1.56%
华盛通- 最 高8.72
- 今 开8.33
- 成交量 186.75万股
- 最 低 8.14
- 昨 收 8.34
- 总市值 7.32亿
- 52周最高 8.72
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.76
- 委 比 -64.15%
- 总股本 8914.11万
- 历史最高 41.9297
- 量 比 1.06
- 振 幅 6.95%
- 历史最低 1.575
- 每 手 1
- 风险率 1.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery
Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with post-bariatric hypoglycemia.
07-15 02:15
美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
Goldman Sachs Reinstates Buy on Amylyx Pharmaceuticals, Announces $10 Price Target
Goldman Sachs analyst Corinne Johnson reinstates Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and announces $10 price target.
07-11 02:12
Amylyx to Spotlight Breakthrough Hypoglycemia Drug Avexitide at ENDO 2025 Investor Event
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that it will host an investor event at the Endocrine Society's annual meeting (ENDO 2025) on Sunday, July 13, 2025, at 6:00 p.m. PT,
07-08 19:03
美股牛股 | 纳比特大涨超36%，公司宣布为币安币储备大额可转换票据；内克塔治疗飙升逾150%
纳比特大涨超36%，公司宣布为币安币储备大额可转换票据；内克塔治疗飙升逾150%，皮炎药物临床试验结果良好；安霸拟考虑出售公司，隔夜涨超20%>>
06-25 19:15
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market
Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity.
06-25 02:59
Guggenheim Initiates Coverage On Amylyx Pharmaceuticals with Buy Rating, Announces Price Target of $17
Guggenheim analyst Seamus Fernandez initiates coverage on Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy rating and announces Price Target of $17.
06-24 20:10
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
Citigroup Initiates Coverage On Amylyx Pharmaceuticals with Buy Rating, Announces Price Target of $12
Citigroup analyst Geoff Meacham initiates coverage on Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy rating and announces Price Target of $12.
06-17 19:37
